Skip to content

A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526343-35-00
Enrollment
52
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Sponsors

Pharmability AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 17, 2026